Patient characteristics
| . | All, N = 236 (100%) . | Intermediate risk II (ELN), N = 70 (30%) . | Adverse risk (ELN), no abnl(17p)/no −5/5q−, N = 95 (40%) . | Adverse riks (ELN), no abnl(17p) but −5/5q−, N = 41 (17%) . | abnl(17p), N = 30 (13%) . |
|---|---|---|---|---|---|
| Median age (at time of diagnosis), y | 55 | 55 | 53 | 58 | 55 |
| Range | 21-77 | 22-75 | 21-77 | 28-69 | 30-71 |
| De novo AML/sAML/t-MN | |||||
| De novo | 142 (60) | 46 (66) | 60 (63) | 21 (51) | 15 (50) |
| sAML | 62 (26) | 15 (21) | 19 (20) | 17 (42) | 11 (37) |
| t-MN | 32 (14) | 9 (13) | 16 (17) | 3 (7) | 4 (13) |
| Treatment status | |||||
| Firstline | 187 (79) | 53 (76) | 72 (76) | 36 (88) | 26 (87) |
| Salvage | 49 (21) | 17 (24) | 23 (24) | 5 (12) | 4 (13) |
| Monosomal karyotype | |||||
| No | 171 (72) | 70 (100) | 76 (80) | 16 (39) | 9 (30) |
| Yes | 65 (28) | 19 (20) | 25 (61) | 21 (70) | |
| Karnofsky index* | |||||
| ≥ 80% | 213 (91) | 65 (94) | 83 (87) | 38 (95) | 27 (90) |
| < 80% | 21 (9) | 4 (6) | 12 (13) | 2 (5) | 3 (10) |
| Sorror index† | |||||
| Low risk | 55 (24) | 18 (27) | 20 (21) | 9 (22) | 8 (28) |
| Intermediate risk | 64 (28) | 16 (24) | 35 (37) | 8 (20) | 5 (17) |
| High risk | 113 (49) | 33 (49) | 40 (42) | 24 (59) | 16 (55) |
| Marrow blasts prior to HSCT‡ | |||||
| < 5% blasts | 141 (61) | 42 (61) | 61 (64) | 21 (53) | 17 (59) |
| 5%-20% blasts | 44 (19) | 14 (20) | 16 (17) | 8 (20) | 6 (21) |
| > 20% blasts | 48 (21) | 13 (19) | 18 (19) | 11 (28) | 6 (21) |
| Conditioning intensity | |||||
| Myeloablative | 38 (16) | 8 (11) | 18 (19) | 7 (17) | 5 (17) |
| Reduced intensity | 115 (49) | 33 (47) | 50 (53) | 19 (46) | 13 (43) |
| FLAMSA | 63 (27) | 19 (27) | 22 (23) | 13 (32) | 9 (30) |
| Flu/2 Gy | 20 (8) | 10 (14) | 5 (5) | 2 (5) | 3 (10) |
| Donor source | |||||
| Sibling | 62 (26) | 17 (24) | 29 (31) | 10 (24) | 6 (20) |
| Matched unrelated donor, 8/8 | 116 (49) | 33 (47) | 46 (48) | 22 (54) | 15 (50) |
| Partially unrelated donor | 58 (25) | 20 (29) | 20 (21) | 9 (22) | 9 (30) |
| Sex match | |||||
| Male recipient-female donor | 34 (14) | 8 (11) | 15 (16) | 7 (17) | 4 (13) |
| Any other | 202 (86) | 62 (89) | 80 (84) | 34 (83) | 26 (87) |
| CMV status§ | |||||
| Neg-neg | 50 (22) | 13 (19) | 25 (28) | 6 (15) | 6 (20) |
| Pos recipient | 146 (64) | 43 (63) | 53 (59) | 32 (78) | 18 (60) |
| Neg recipient–pos donor | 33 (14) | 12 (18) | 12 (13) | 3 (7) | 6 (20) |
| . | All, N = 236 (100%) . | Intermediate risk II (ELN), N = 70 (30%) . | Adverse risk (ELN), no abnl(17p)/no −5/5q−, N = 95 (40%) . | Adverse riks (ELN), no abnl(17p) but −5/5q−, N = 41 (17%) . | abnl(17p), N = 30 (13%) . |
|---|---|---|---|---|---|
| Median age (at time of diagnosis), y | 55 | 55 | 53 | 58 | 55 |
| Range | 21-77 | 22-75 | 21-77 | 28-69 | 30-71 |
| De novo AML/sAML/t-MN | |||||
| De novo | 142 (60) | 46 (66) | 60 (63) | 21 (51) | 15 (50) |
| sAML | 62 (26) | 15 (21) | 19 (20) | 17 (42) | 11 (37) |
| t-MN | 32 (14) | 9 (13) | 16 (17) | 3 (7) | 4 (13) |
| Treatment status | |||||
| Firstline | 187 (79) | 53 (76) | 72 (76) | 36 (88) | 26 (87) |
| Salvage | 49 (21) | 17 (24) | 23 (24) | 5 (12) | 4 (13) |
| Monosomal karyotype | |||||
| No | 171 (72) | 70 (100) | 76 (80) | 16 (39) | 9 (30) |
| Yes | 65 (28) | 19 (20) | 25 (61) | 21 (70) | |
| Karnofsky index* | |||||
| ≥ 80% | 213 (91) | 65 (94) | 83 (87) | 38 (95) | 27 (90) |
| < 80% | 21 (9) | 4 (6) | 12 (13) | 2 (5) | 3 (10) |
| Sorror index† | |||||
| Low risk | 55 (24) | 18 (27) | 20 (21) | 9 (22) | 8 (28) |
| Intermediate risk | 64 (28) | 16 (24) | 35 (37) | 8 (20) | 5 (17) |
| High risk | 113 (49) | 33 (49) | 40 (42) | 24 (59) | 16 (55) |
| Marrow blasts prior to HSCT‡ | |||||
| < 5% blasts | 141 (61) | 42 (61) | 61 (64) | 21 (53) | 17 (59) |
| 5%-20% blasts | 44 (19) | 14 (20) | 16 (17) | 8 (20) | 6 (21) |
| > 20% blasts | 48 (21) | 13 (19) | 18 (19) | 11 (28) | 6 (21) |
| Conditioning intensity | |||||
| Myeloablative | 38 (16) | 8 (11) | 18 (19) | 7 (17) | 5 (17) |
| Reduced intensity | 115 (49) | 33 (47) | 50 (53) | 19 (46) | 13 (43) |
| FLAMSA | 63 (27) | 19 (27) | 22 (23) | 13 (32) | 9 (30) |
| Flu/2 Gy | 20 (8) | 10 (14) | 5 (5) | 2 (5) | 3 (10) |
| Donor source | |||||
| Sibling | 62 (26) | 17 (24) | 29 (31) | 10 (24) | 6 (20) |
| Matched unrelated donor, 8/8 | 116 (49) | 33 (47) | 46 (48) | 22 (54) | 15 (50) |
| Partially unrelated donor | 58 (25) | 20 (29) | 20 (21) | 9 (22) | 9 (30) |
| Sex match | |||||
| Male recipient-female donor | 34 (14) | 8 (11) | 15 (16) | 7 (17) | 4 (13) |
| Any other | 202 (86) | 62 (89) | 80 (84) | 34 (83) | 26 (87) |
| CMV status§ | |||||
| Neg-neg | 50 (22) | 13 (19) | 25 (28) | 6 (15) | 6 (20) |
| Pos recipient | 146 (64) | 43 (63) | 53 (59) | 32 (78) | 18 (60) |
| Neg recipient–pos donor | 33 (14) | 12 (18) | 12 (13) | 3 (7) | 6 (20) |
ELN indicates European LeukemiaNet; abnl (17p), abnormality of chromosome 17p; AML, acute myeloid leukemia; sAML, secondary AML; t-MN, treatment-related AML; HSCT, hematopoietic stem cell transplantation; FLAMSA, chemotherapy with fludarabine, amsacrine, cytarabine, and subsequent reduced-intensity conditioning; Flu, fludarabine; CMV, cytomegalovirus; pos, positive; and neg, negative.
Data on *2 patients, †4 patients, ‡3 patients, and §7 patients are missing. Patients with available information add to 100%.